Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Man... ( WESTMINSTER Colo. Jan. 28 /- Allo...)

Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing

Date:1/28/2008

WESTMINSTER, Colo., Jan. 28 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the appointment of Bruce K. Bennett as Vice President, Manufacturing. In this position, Mr. Bennett will lead the Company's manufacturing functions to support the continued development and potential commercialization of Allos' product candidates.

"We are delighted to welcome Bruce to Allos," said Paul L. Berns, President and CEO. "Bruce's experience in all aspects of pharmaceutical manufacturing and his demonstrated leadership in the pharmaceutical, biotechnology and life sciences industries will be valuable as we look to advance our product candidates in support of our mission of developing and commercializing promising new therapies for cancer patients."

Mr. Bennett has over 25 years of manufacturing experience in the pharmaceutical, medical device and biotechnology industries. Since 2006, Mr. Bennett has served as an independent consultant focused on the development of business operations, technical and supply chain solutions for biotechnology and pharmaceutical companies. From 2002 to 2006, Mr. Bennett served as Vice President, Manufacturing at La Jolla Pharmaceuticals, where he led a 50 member team in manufacturing, materials management, vendor and commercial development, quality control, validation, engineering, facilities, and environmental health and safety. Prior to La Jolla, Mr. Bennett served as Vice President, Operations at Provasis Therapeutics from 2000 to 2002, and as Vice President, Operations, RA/QA/QC and Commercial Development at Via Medical Corporation from 1997 to 2000. From 1987 to 1997, Mr. Bennett served as a senior operations executive of various pharmaceutical, biotechnology and other compan
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference
2. Allos Therapeutics Reports Third Quarter 2007 Financial Results
3. Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference
4. Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
5. Transition Therapeutics Announces Appointment of Vice-President of Business Development
6. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
7. Transition Therapeutics Announces Milestone Payment from Elan
8. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
9. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
10. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
11. Dr. Peter B. Corr Joins Team at Celtic Therapeutics as General Partner

Post Your Comments:

(Date:5/22/2013)... 21 May 2013, Paris, France: Results from ... 2013 today question whether bivalirudin is superior ... blockade, showing similar 30-day mortality in patients ... (NSTE-ACS) undergoing percutaneous coronary intervention (PCI)., European ... alone as an alternative to unfractionated heparin ...

(Date:5/22/2013)... 2013 In the past decade, ... and courts with donated uniforms, shoes, balls and ... dedicated to partnering with manufacturers to provide youth with ... of $8.8 million in sports and fitness equipment over ... kids outfitted for physical activity. , An inaugural ...

(Date:5/22/2013)... Following the success of last year’s 1,000 ... Body Boot Camp Kincardine has announced it will be ... on June 3rd at its Kincardine fitness center ... Ontario. , Fit Body Boot Camp’s 1,000 lb. Meltdown ... residents to lose a total of 1,000 pounds in ...

(Date:5/22/2013)... NJ (PRWEB) May 22, 2013 ... and management solutions for social enterprise collaboration platforms, ... a consulting firm based in Chicago, Ill. The ... their products and provide best-in-class solutions for SharePoint ... improve collaboration. , AvePoint’s DocAve Software Platform ...

(Date:5/22/2013)... 2013 Poor adherence to appropriate medication ... medical complications and death (some 125,000 deaths in the ... increased health-care costs. It’s been estimated that between 33% ... to poor medication adherence — a reality that costs ... Indeed, so dire is the degree of medication non-adherence ...

Breaking Medicine News(10 mins):Health News:Registry questions superiority of bivalirudin over heparin 2 Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2 Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3 Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2 Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3 Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 2 Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 3 Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2

[0] Registry questions superiority of bivalirudin over heparin [0] Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity [0] Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity [0] AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration [0] Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance

... PHILADELPHIA, Nov. 13 Lippincott Williams & Wilkins (LWW) ... Nurses Association (HPNA) has appointed Betty Ferrell, PhD, MA, ... of Hospice & Palliative Nursing. LWW is part of ... business intelligence for students, professionals, and institutions in medicine, ...

... to Create 1,500 Jobs , HERSHEY, Pa., Nov. 13 ... on the new Penn State Hershey Children,s Hospital and said ... economy, but most importantly, for sick children and their families. ... and another 1,200 jobs once the facility is completed. , ...

... to absorb potent antioxidant , FRIDAY, Nov. 13 (HealthDay ... of the yellow curry ingredient curcumin, which is being ... cancer, psoriasis and Alzheimer,s disease. , Curcumin, the active ... However, digestive juices in the gastrointestinal tract quickly destroy ...

... Md., Nov. 13 Several weeks ago, the FDA announced ... the post-harvest processing of raw Gulf Coast oysters harvested in ... policy, which would affect about 25% of the total annual ... who suffer severe and painful illness and death from the ...

... Calif., Nov. 13 Human Pheromone Sciences, Inc. (OTC Bulletin ... the three and nine month periods ended September 30, 2009. ... of $273,000 represented a 4% increase from the revenues of ... income of $10,000 ($0.00 per share) as compared with a ...

... ROCHESTER, Minn., Nov. 13 Here are highlights from the ... may cite this publication as often as you wish. Reprinting ... Letter attribution is required. Include the ... www.HealthLetter.MayoClinic.com ...

Cached Medicine News:Health News:Journal of Hospice & Palliative Nursing Names New Editor 2 Health News:Journal of Hospice & Palliative Nursing Names New Editor 3 Health News:Governor Rendell Helps to Break Ground for New Children's Hospital at Penn State Hershey 2 Health News:FDA Statement on Vibrio Vulnificus in Raw Oysters 2 Health News:FDA Statement on Vibrio Vulnificus in Raw Oysters 3 Health News:Human Pheromone Sciences Announces Third Quarter Results 2 Health News:Human Pheromone Sciences Announces Third Quarter Results 3 Health News:Human Pheromone Sciences Announces Third Quarter Results 4 Health News:November 2009 Mayo Clinic Health Letter Highlights Self-Care Tips for Hemorrhoids, Interactive Video Games Improve Health and Heart Failure Treatments 2 Health News:November 2009 Mayo Clinic Health Letter Highlights Self-Care Tips for Hemorrhoids, Interactive Video Games Improve Health and Heart Failure Treatments 3 Health News:November 2009 Mayo Clinic Health Letter Highlights Self-Care Tips for Hemorrhoids, Interactive Video Games Improve Health and Heart Failure Treatments 4 Health News:November 2009 Mayo Clinic Health Letter Highlights Self-Care Tips for Hemorrhoids, Interactive Video Games Improve Health and Heart Failure Treatments 5

Journal of Hospice & Palliative Nursing Names New Editor Governor Rendell Helps to Break Ground for New Children's Hospital at Penn State Hershey Tapping Into Curry's Health Benefits FDA Statement on Vibrio Vulnificus in Raw Oysters Human Pheromone Sciences Announces Third Quarter Results November 2009 Mayo Clinic Health Letter Highlights Self-Care Tips for Hemorrhoids, Interactive Video Games Improve Health and Heart Failure Treatments

(Date:5/22/2013)... May 22, 2013 /PRNewswire-iReach/ -- MarketReportsOnline.com announces addition ... Guidebook Series (4) 2013 Edition Material and Clinical ... Drug Registration: A Guidebook of Registration Application for ... to its online database. The traditional ... are always regarded by occidental as mysterious medicines. ...

(Date:5/22/2013)... VANCOUVER, British Columbia , May 22, 2013 OncoGenex ... the development of novel therapeutics to target mechanisms of treatment ... investigational compounds, custirsen and OGX-427, will be presented as "Trials ... of the American Society of Clinical Oncology (ASCO) in ... 4. Despite the availability of drugs that ...

(Date:5/21/2013)... 2013 Concord Medical Services Holdings Limited ("Concord ... a leading specialty hospital management solution provider and operator ... centers in China and the parent of Chang,an Hospital, ... first quarter ended March 31, 2013 [1] . ... revenue, which consists of net revenues generated from the ...

[0] China Pharmaceutical Market Guidebook Series (4) 2013 Report [0] OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting [0] Concord Medical Reports First Quarter 2013 Financial Results

... 28, 2011 Pharmasset, Inc. (Nasdaq: VRUS ) ... Conference being held May 2 to 4, 2011 at the ... Merrill Lynch Healthcare Conference being held May 10 to 12, ... Price, Pharmasset,s President and Chief Executive Officer, will provide an ...

... 28, 2011 The U.S. Food and Drug ... with prednisone (a steroid) to treat patients with ... prior docetaxel (chemotherapy). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... sex hormone testosterone stimulates prostate tumors to grow. ...

Cached Medicine Technology:Pharmasset to Present at Two Upcoming Investor Conferences 2 Pharmasset to Present at Two Upcoming Investor Conferences 3 FDA Approves Zytiga for Late-Stage Prostate Cancer 2 FDA Approves Zytiga for Late-Stage Prostate Cancer 3

Pharmasset to Present at Two Upcoming Investor Conferences FDA Approves Zytiga for Late-Stage Prostate Cancer

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

Cytology, Oral Scraping or Brushing Specimen Collection Cytology, Gastrointestinal Cytology, Bronchoalveolar Lavage 2 Cytology, Bronchoalveolar Lavage 1